{"id":"optimox-bevacizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Gastrointestinal perforation"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OPTIMOX is an intermittent oxaliplatin-fluorouracil chemotherapy regimen designed to reduce cumulative neurotoxicity while maintaining efficacy. Bevacizumab, a humanized anti-VEGF monoclonal antibody, prevents new blood vessel formation that tumors require for growth and metastasis. The combination leverages chemotherapy cytotoxicity with anti-angiogenic activity to improve outcomes in colorectal cancer.","oneSentence":"OPTIMOX-bevacizumab combines oxaliplatin-based chemotherapy with bevacizumab, a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:45.022Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (first-line treatment)"},{"name":"Advanced colorectal cancer"}]},"trialDetails":[{"nctId":"NCT03828227","phase":"PHASE3","title":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2019-06-14","conditions":"Elderly Patients, Metastatic Colorectal Cancer, Quality of Life","enrollment":49},{"nctId":"NCT01910610","phase":"PHASE3","title":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-10-30","conditions":"Colorectal Cancer Metastatic","enrollment":464},{"nctId":"NCT00265824","phase":"PHASE3","title":"Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2005-05","conditions":"Colorectal Cancer","enrollment":700},{"nctId":"NCT00499369","phase":"PHASE3","title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-06","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Folinic acid (FA)-5-fluorouracil (5-FU)-oxaliplatin [OPTIMOX]","Avastin"],"phase":"phase_3","status":"active","brandName":"OPTIMOX-bevacizumab","genericName":"OPTIMOX-bevacizumab","companyName":"GERCOR - Multidisciplinary Oncology Cooperative Group","companyId":"gercor-multidisciplinary-oncology-cooperative-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OPTIMOX-bevacizumab combines oxaliplatin-based chemotherapy with bevacizumab, a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis. Used for Metastatic colorectal cancer (first-line treatment), Advanced colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}